216 related articles for article (PubMed ID: 23879512)
41. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
42. Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis.
Bottolo L; Miller S; Johnson SR
Thorax; 2020 Aug; 75(8):679-688. PubMed ID: 32467337
[TBL] [Abstract][Full Text] [Related]
43. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
[TBL] [Abstract][Full Text] [Related]
44. Involvement of lymphatics in lymphangioleiomyomatosis.
Glasgow CG; Taveira-DaSilva A; Pacheco-Rodriguez G; Steagall WK; Tsukada K; Cai X; El-Chemaly S; Moss J
Lymphat Res Biol; 2009 Dec; 7(4):221-8. PubMed ID: 20143921
[TBL] [Abstract][Full Text] [Related]
45. [A rare cause of edema: sporadic lymphangioleiomyomatosis].
Frank H; Weiss W
Dtsch Med Wochenschr; 2013 Sep; 138(38):1892-5. PubMed ID: 24022453
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
Budde K; Zonnenberg BA; Frost M; Cheung W; Urva S; Brechenmacher T; Stein K; Chen D; Kingswood JC; Bissler JJ
Br J Clin Pharmacol; 2016 May; 81(5):958-70. PubMed ID: 26580489
[TBL] [Abstract][Full Text] [Related]
47. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM).
Xu KF; Zhang P; Tian X; Ma A; Li X; Zhou J; Zeng N; Gui YS; Guo Z; Feng R; Zhang W; Sun W; Cai B
Respir Med; 2013 Feb; 107(2):263-8. PubMed ID: 23127572
[TBL] [Abstract][Full Text] [Related]
48. Clinical and histopathological alterations of lymphangioleiomyomatosis in 14 Chinese patients.
Lu SH; Hou YY; Tan YS; Xu JF; Zeng HY; Sujie AK; Wang XD; Bai CX
Chin Med J (Engl); 2009 Aug; 122(16):1895-900. PubMed ID: 19781367
[TBL] [Abstract][Full Text] [Related]
49. Meningiomas in lymphangioleiomyomatosis.
Moss J; DeCastro R; Patronas NJ; Taveira-DaSilva A
JAMA; 2001 Oct; 286(15):1879-81. PubMed ID: 11597290
[TBL] [Abstract][Full Text] [Related]
50. Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis.
Harari S; Spagnolo P; Cocconcelli E; Luisi F; Cottin V
Curr Opin Pulm Med; 2018 Sep; 24(5):469-476. PubMed ID: 29927757
[TBL] [Abstract][Full Text] [Related]
51. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
[TBL] [Abstract][Full Text] [Related]
52. Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Shawker T; Glasgow CG; Stylianou M; Moss J
Chest; 2015 Oct; 148(4):1027-1033. PubMed ID: 26066372
[TBL] [Abstract][Full Text] [Related]
53. Lymphatic manifestations of lymphangioleiomyomatosis.
Gupta R; Kitaichi M; Inoue Y; Kotloff R; McCormack FX
Lymphology; 2014 Sep; 47(3):106-17. PubMed ID: 25420303
[TBL] [Abstract][Full Text] [Related]
54. Peritoneovenous shunt for chylous ascites after lung transplantation for lymphangioleiomyomatosis.
Kanou T; Nakagiri T; Minami M; Inoue M; Shintani Y; Okumura M
Transplant Proc; 2012 Jun; 44(5):1390-3. PubMed ID: 22664021
[TBL] [Abstract][Full Text] [Related]
55. Lymphangioleiomyomatosis: differential diagnosis and optimal management.
Xu KF; Lo BH
Ther Clin Risk Manag; 2014; 10():691-700. PubMed ID: 25187723
[TBL] [Abstract][Full Text] [Related]
56. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
[TBL] [Abstract][Full Text] [Related]
57. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
[TBL] [Abstract][Full Text] [Related]
58. Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.
Huang YL; Chen PR; Lai YJ; Hsu HH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445268
[TBL] [Abstract][Full Text] [Related]
59. Lymphangioleiomyomatosis.
Johnson SR; Taveira-DaSilva AM; Moss J
Clin Chest Med; 2016 Sep; 37(3):389-403. PubMed ID: 27514586
[TBL] [Abstract][Full Text] [Related]
60. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
